• Main page
• About the journal
• Editorial board
• Subscription
• Information for contributors
• Editorial and Peer Review
• Issues archive
• Authors
• Articles
  • By alphabet
  • By category
• Blogs and comments

The journal is included into The list of leading scientific periodicals.

The journal is included into VINITI database and is registered in Electronic scientific library.

The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.

EBSCO

https://doi.org/10.14300/mnnc.2020.15011

Diverticular disease of the colon and its assotiation with polyps and colorectal cancer: a clinical, instrumental and immunomorphological study

[Original research]
Mikhail Osadchuk; Andrey Svistunov; Alexandra Zolotovitskaya; Vladimir Reshetnikov; Vasiliy Kozlov; Ekaterina Dmitrievna Mironova; Maksim Osadchuk; Ekaterina Sergeevna Ogibenina;

Presently the development of early prognostic criteria for the course of diverticular colon disease (DCD) based on proliferation indicators such as Kisspeptin1 (KISS1), p53, chromogranin-A (CgA) is particularly relevant. The aim of the study was to determine the role of clinical endoscopic and immunomorphological parameters in patients with DCD and in combination with adenomatous intestinal polyps (APC) and colorectal cancer (CRC). We examined 190 patients with DCD (120), comorbid to CRC (15) and APC (55), and 28 healthy people. According to the results, the expression of p53 in the DCD group with CRC is higher than the average value in the group of healthy subjects (0.34 and 0.16). Expression of the KISS1 receptor (KISS1R) in individuals with DCD in combination with APC was decreased, while in patients with CRC it was completely absent. CgA expression increased in patients with DCD and reached maximum values in CRC. Thus, DCD and its combination with APC and CRC have both common pathogenetic mechanisms and differences in immunomorphological parameters, and in the number of neuroendocrine cells of the gastric mucosa secreting KISS1R, p53, and CgA.

Download

References:
1. Everhart J. E., Ruhl C. E. Burden of digestive diseases in the United States part II: lower gastrointestinal diseases. Gastroenterology. 2009;136(3):741-754. https://doi.org/10.1053/j.gastro.2009.01.015
2. Meurs-Szojda M. M., Terhaar sive Droste J. S., Kuik D. J., Mulder C. J. J., Felt-Bersma R. J. F. Diverticulosis and diverticulitis form no risk for polyps and colorectal neoplasia in 4,241 colonoscopies. Int. J. Colorectal. Dis. 2008;23(10):979-984. https://doi.org/10.1007/s00384-008-0510-4
3. Regula J. Diverticular Disease and Colorectal Cancer: Incidental Diagnosis or Real Association? Final Answer. J. Clin. Gastroenterol. 2016;50 Suppl.1:S39-40. https://doi.org/10.1097/MCG.0000000000000643
4. Lee J. H., Miele M. E., Hicks D. J. [et al.]. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J. Natl. Cancer Inst. 1996;88(23):1731-1737. https://doi.org/10.1093/jnci/88.23.1731
5. Mead E. J., Maguire J. J., Kuc R. E., Davenport A. P. Kisspeptins: a multifunctional peptide system with a role in reproduction, cancer and the cardiovascular system. Br. J. Pharmacol. 2007;151(8):1143-1153. https://doi.org/10.1038/sj.bjp.0707295
6. Chen S., Su X., Gao J., Han H., Chen Z., Lin S. Suppression of Kiss-1 gene inhibits HCT116 human colorectal carcinoma cell migration in vitro via nuclear factor-κB signaling pathway. Nan Fang Yi Ke Da Xue Xue Bao. 2015;35(11):1643-1648.
7. Sato K., Shirai R., Hontani M. [et al.]. Potent Vasoconstrictor Kisspeptin-10 Induces Atherosclerotic Plaque Progression and Instability: Reversal by its Receptor GPR54 Antagonist. J. Am. Heart Assoc. 2017;6(4). https://doi.org/10.1161/JAHA.117.005790
8. Sawyer I., Smillie S. J., Bodkin J. V., Fernandes E., O’Byrne K. T., Brain S. D. The vasoactive potential of kisspeptin-10 in the peripheral vasculature. PLoS ONE. 2011;6(2):e14671. https://doi.org/10.1371/journal.pone.0014671
9. Nash K. T., Welch D. R. The KISS1 metastasis suppressor: mechanistic insights and clinical utility. Front. Biosci. 2006;11:647-659. https://doi.org/10.2741/1824
10. Wang P., Liang J., Wang Z., Hou H., Shi L., Zhou Z. The prognostic value of p53 positive in colorectal cancer: A retrospective cohort study. Tumour Biol. 2017;39(5):1010428317703651. https://doi.org/10.1177/1010428317703651
11. Liu Y., He J., Xu J. [et al.]. Neuroendocrine differentiation is predictive of poor survival in patients with stage II colorectal cancer. Oncol. Lett. 2017;13(4):2230-2236. https://doi.org/10.3892/ol.2017.5681
12. Al-Kindi S. G., Oliveira G. H. Prevalence of Preexisting Cardiovascular Disease in Patients With Different Types of Cancer: The Unmet Need for Onco-Cardiology. Mayo Clin. Proc. 2016;91(1):81-83. https://doi.org/10.1016/j.mayocp.2015.09.009
13. Kim T. J., Kim E. R., Chang D. K. [et al.]. Helicobacter pylori infection is an independent risk factor of early and advanced colorectal neoplasm. Helicobacter. 2017;22(3). https://doi.org/10.1111/hel.12377
14. Ghanghas P., Jain S., Rana C., Sanyal S. N. Chemoprevention of Colon Cancer through Inhibition of Angiogenesis and Induction of Apoptosis by Nonsteroidal Anti-Inflammatory Drugs. J. Environ. Pathol. Toxicol. Oncol. 2016;35(3):273-289. https://doi.org/10.1615/JEnvironPatholToxicolOncol.2016015704
15. Juneja M., Kobelt D., Walther W. [et al.]. Statin and rottlerin small-molecule inhibitors restrict colon cancer progression and metastasis via MACC1. PLoS Biol. 2017;15(6):e2000784. https://doi.org/10.1371/journal.pbio.2000784
16. Yokomichi H., Nagai A., Hirata M. [et al.]. Statin use and all-cause and cancer mortality: BioBank Japan cohort. J.Epidemiol. 2017;27(3S):S84-S91. https://doi.org/10.1016/j.je.2016.12.011
17. Rodriguez-Broadbent H., Law P. J., Sud A. [et al.]. Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer. Int. J. Cancer. 2017;140(12):2701-2708. https://doi.org/10.1002/ijc.30709
18. Mahamid M., Abu-Elhija O., Yassin T., Nseir W. Advanced Hepatic Fibrosis in Fatty Liver Disease Linked to Hyperplastic Colonic Polyp. Can. J. Gastroenterol. Hepatol. 2017;2017:2054871. https://doi.org/10.1155/2017/2054871
19. Kondo T., Okabayashi K., Hasegawa H., Tsuruta M., Shigeta K., Kitagawa Y. The impact of hepatic fibrosis on the incidence of liver metastasis from colorectal cancer. Br. J. Cancer. 2016;115(1):34-39. https://doi.org/10.1038/bjc.2016.155
20. Mulder J. W., Offerhaus G. J., de Feyter E. P. [et al.]. The relationship of quantitative nuclear morphology to molecular genetic alterations in the adenoma-carcinoma sequence of the large bowel. Am. J. Pathol. 1992;141(4):797-804.
21. Ohman L., Stridsberg M., Isaksson S., Jerlstad P., Simrén M. Altered levels of fecal chromogranins and secretogranins in IBS: relevance for pathophysiology and symptoms? Am. J. Gastroenterol. 2012;107(3):440-447. https://doi.org/10.1038/ajg.2011.458
22. Hao Y., Shan G., Nan K. Establishment of apoptotic regulatory network for genetic markers of colorectal cancer. Saudi J. Biol. Sci. 2017;24(3):466-476. https://doi.org/10.1016/j.sjbs.2017.01.014
23. El-Salhy M., Gilja O. H. Abnormalities in ileal stem, neurogenin 3, and enteroendocrine cells in patients with irritable bowel syndrome. BMC Gastroenterol. 2017;17(1):90. https://doi.org/10.1186/s12876-017-0643-4
24. Welin S., Stridsberg M., Cunningham J. [et al.]. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology. 2009;89(3):302-307. https://doi.org/10.1159/000179900
25. Mujagic Z., Jonkers D. M. a. E., Ludidi S. [et al.]. Biomarkers for visceral hypersensitivity in patients with irritable bowel syndrome. Neurogastroenterol. Motil. 2017;29(12). https://doi.org/10.1111/nmo.13137

Keywords: diverticular disease of the colon, kisspeptin1 (KISS1), p53, chromogranin-A (CgA)